Stage-specific guided adjuvant treatment for gastric cancer

Annals of Surgical Oncology

Volumn 15, Issue 9, 2008, Pages 2622-2623

  Liakakos, T ^a   Fatourou, E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TUMOR MARKER;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; EARLY CANCER; LETTER; PRACTICE GUIDELINE; STOMACH CANCER;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SEER PROGRAM; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 50049083237     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9913-2     Document Type: Letter

References (30)

1. NG Coburn A Govindarajan CH Law 2008 Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients Ann Surg Oncol 15 500 7
2. E Briasoulis T Liakakos L Dova 2006 Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer Expert Rev Anticancer Ther 6 931 9
3. DH Roukos 2002 Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9 220 1
4. E Briasoulis M Fatouros DH Roukos 2007 Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14 2691 5
5. DH Roukos AM Kappas 2005 Perspectives in the treatment of gastric cancer Nat Clin Pract Oncol 2 98 107
6. S Sakuramoto M Sasako T Yamaguchi 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 20
7. D Cunningham WH Allum SP Stenning 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20
8. JS Macdonald SR Smalley J Benedetti 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinomas of the stomach or gastroesophageal junction N Engl J Med 345 725 30
9. T Liakakos DH Roukos 2008 More controversy than ever - challenges and promises towards personalized treatment of gastric cancer Ann Surg Oncol 15 956 60
10. DH Roukos AM Kappas 2002 Targeting the optimal extent of lymph node dissection for gastric cancer J Surg Oncol 81 59 62
11. AM Kappas M Fatouros DH Roukos 2004 Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11 727 30
12. DH Roukos 1998 Extended lymphadenectomy in gastric cancer: when, for whom and why Ann R Coll Surg Engl 80 16 24
13. DH Roukos 2000 Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7 253 5
14. DH Roukos C Hottenrott A Encke 1994 Primary gastric lymphomas: a clinicopathologic study with literature review Surg Oncol 3 115 25
15. DH Roukos 2004 Early-stage gastric cancer: a highly treatable disease Ann Surg Oncol 11 127 9
16. DH Roukos M Lorenz A Encke 1998 Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study Surgery 123 573 8
17. DH Roukos S Murray E Briasoulis 2007 Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer Cancer Biol Ther 6 308 12
18. DH Roukos AM Kappas E Tsianos 2002 Role of surgery in the prophylaxis of hereditary cancer syndromes Ann Surg Oncol 9 607 9
19. JA Norton CM Ham J Van Dam 2007 CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer Ann Surg 245 873 9
20. DH Roukos E Briasoulis 2007 Individualized preventive and therapeutic management of hereditary breast ovarian cancer Nat Clin Pract Oncol 4 578 90
21. DH Roukos 2008 Linking contralateral breast cancer with genetics Radiother Oncol 86 139 41
22. DH Roukos 2007 Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med 357 1555 6 author reply 1556
23. M Fatouros G Baltoyiannis DH Roukos 2008 The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations Ann Surg Oncol 15 21 33
24. DH Roukos NJ Agnanti E Paraskevaidis 2002 Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations Ann Surg Oncol 9 941 3
25. NJ Agnantis E Paraskevaidis D Roukos 2004 Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance Ann Surg Oncol 11 1030 4
26. DH Roukos AM Kappas NJ Agnantis 2003 Perspectives and risks of breast-conservation therapy for breast cancer Ann Surg Oncol 10 718 21
27. M Fatouros DH Roukos I Arampatzis 2005 Factors increasing local recurrence in breast-conserving surgery Expert Rev Anticancer Ther 5 737 45
28. DH Roukos 2008 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 358 197
29. DH Roukos 2008 Breast-cancer stromal cells with TP53 mutations N Engl J Med 358 15 1636
30. DH Roukos 2008 Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies Expert Rev Mol Diagn 8 29 39